Your browser doesn't support javascript.
loading
Metabolic Plasticity in Chemotherapy Resistance.
Desbats, Maria Andrea; Giacomini, Isabella; Prayer-Galetti, Tommaso; Montopoli, Monica.
Afiliação
  • Desbats MA; Department of Medicine, University of Padova, Padova, Italy.
  • Giacomini I; Veneto Institute of Molecular Medicine, Padova, Italy.
  • Prayer-Galetti T; Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Montopoli M; U.O.C. Urology, Azienda Ospedaliera di Padova, Padova, Italy.
Front Oncol ; 10: 281, 2020.
Article em En | MEDLINE | ID: mdl-32211323
ABSTRACT
Resistance of cancer cells to chemotherapy is the first cause of cancer-associated death. Thus, new strategies to deal with the evasion of drug response and to improve clinical outcomes are needed. Genetic and epigenetic mechanisms associated with uncontrolled cell growth result in metabolism reprogramming. Cancer cells enhance anabolic pathways and acquire the ability to use different carbon sources besides glucose. An oxygen and nutrient-poor tumor microenvironment determines metabolic interactions among normal cells, cancer cells and the immune system giving rise to metabolically heterogeneous tumors which will partially respond to metabolic therapy. Here we go into the best-known cancer metabolic profiles and discuss several studies that reported tumors sensitization to chemotherapy by modulating metabolic pathways. Uncovering metabolic dependencies across different chemotherapy treatments could help to rationalize the use of metabolic modulators to overcome therapy resistance.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália